Expanded Access for Marizomib
NCT04644107 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2020-11-25
Summary
This is an expanded access program (EAP) for eligible participants designed to provide access to Marizomib.
Conditions
Interventions
- DRUG
-
Marizomib
Marizomib will be administered via IV
Sponsors & Collaborators
-
Celgene
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
Safety Study of AMG 228 to Treat Solid Tumors
NCT02437916 ·Status: TERMINATED ·Phase: PHASE1
-
Expanded Access Protocol for Subjects With Relapsed or Refractory Advanced Solid Tumors Receiving TJ210001
NCT05511350 ·Status: NO_LONGER_AVAILABLE
-
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
NCT06452160 ·Status: RECRUITING ·Phase: PHASE1
-
A Research Study of JNJ-26854165 to Determine the Safety and Dose in Patients With Advanced Stage or Refractory Solid Tumors.
NCT00676910 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
NCT02760797 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of NX-1607 in Adults With Advanced Malignancies
NCT05107674 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
NCT02108652 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors
NCT02298387 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors
NCT05389462 ·Status: TERMINATED ·Phase: PHASE1
-
Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors
NCT04747470 ·Status: TERMINATED ·Phase: PHASE1
-
QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors
NCT00974896 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors
NCT00886782 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Expanded Access to ABBV-CLS-484
NCT06188975 ·Status: AVAILABLE
-
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
NCT06234397 ·Status: RECRUITING ·Phase: PHASE1
-
Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer
NCT04504513 ·Status: APPROVED_FOR_MARKETING
-
Expanded Access to ABBV-787
NCT06439966 ·Status: NO_LONGER_AVAILABLE
-
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
NCT01723020 ·Status: COMPLETED ·Phase: PHASE1
-
A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumors
NCT05908773 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer
NCT05159440 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
NCT07182149 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors
NCT00813384 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma
NCT00121680 ·Status: COMPLETED ·Phase: PHASE1
-
Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors
NCT06872489 ·Status: AVAILABLE
-
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NCT06131398 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer
NCT00214838 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2